Efficacy of partially hydrolyzed guar gum (PHGG) supplemented modified oral rehydration solution in the treatment of severely malnourished children with watery diarrhoea: a randomised double-blind controlled trial

被引:16
|
作者
Alam, Nur Haque [1 ]
Ashraf, Hasan [1 ]
Kamruzzaman, Mohammad [1 ]
Ahmed, Tahmeed [1 ]
Islam, Sufia [2 ]
Olesen, Maryam Kadjar [3 ]
Gyr, Niklaus [4 ]
Meier, Remy [5 ]
机构
[1] Icddr B, Dhaka, Bangladesh
[2] East West Univ, Dept Pharm, Dhaka, Bangladesh
[3] Nestle Hlth Care Nutr, Gland, Switzerland
[4] Univ Basel Hosp, Dept Internal Med, CH-4031 Basel, Switzerland
[5] Kantonsspital, Dept Gastroenterol Hepatol & Nutr, Liestal, Switzerland
关键词
Diarrhoea; Severe malnutrition; Children; Partially hydrolyzed guar gum (PHGG); CHAIN FATTY-ACIDS; AMYLASE-RESISTANT STARCH; PERSISTENT DIARRHEA; CHILDHOOD DIARRHEA; RURAL BANGLADESH; GREEN BANANA; MANAGEMENT; COLON; ABSORPTION; MALNUTRITION;
D O I
10.1186/s41043-015-0003-3
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Objectives: To examine whether PHGG added ORS reduce duration of diarrhoea, stool output and enhance weight gain. Methods: In a double-blind controlled clinical trial, 126 malnourished children (weight for length/weight for age < -3 Z-score with or without pedal edema), aged 6 - 36 months with acute diarrhoea < 7 days were studied in two treatment groups; 63 received modified WHO ORS (Na 75, K 40, Cl 87, citrate 7, glucose 90 mmol/L) with PHGG 15 g/L (study group); 63 received modified WHO ORS without PHGG (control). Other treatments were similar in both groups. The study protocol was approved by Ethics Committee of icddr,b; the study was carried out at the Dhaka Hospital. Results: The mean duration of diarrhoea (h) was significantly shorter in children of the study group (Study vs. control, mean +/- SD, 57 +/- 31 vs. 75 +/- 39, p = 0.01). Although there was a trend in stool weight reduction in children receiving ORS with PHGG (study vs. control, stool weight (g), mean +/- SD; 1st 24 hour, 854.03 +/- 532.15 vs. 949.11 +/- 544.33, p = 0.32; 2nd 24 hour, 579.84 +/- 466.01 vs. 761.26 +/- 631.64, p = 0.069; 3rd 24 hour, 385.87 +/- 454.09 vs. 495.73 +/- 487.61, p = 0.196), especially in 2nd 24 h period, the difference was not statistically significant. The mean time (day) to attain weight for length 80% of NCHS median without edema was significantly shorter in the study group (study vs. control, mean +/- SD, 4.5 +/- 2.6 vs. 5.7 +/- 2.8, p = 0.027). Conclusion: PHGG added to ORS substantially reduced duration of diarrhoea. It also enhanced weight gain. Further studies might substantiate to establish its beneficial effect.
引用
收藏
页数:9
相关论文
共 39 条
  • [31] Efficacy of levetiracetam in the treatment of children with BECTS: A prospective, open-label pilot trial prior to a controlled, randomised, double-blind German multicentre study (HEAD-Study)
    Bonfert, M.
    Armbruster, S.
    Bastian, B.
    Heinen, F.
    EPILEPSIA, 2006, 47 : 133 - 133
  • [32] Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL)
    Barrera, Carlos M.
    Mykietiuk, Analia
    Metev, Hristo
    Nitu, Mimi Floarea
    Karimjee, Najumuddin
    Doreski, Pablo Alexis
    Mitha, Ismail
    Tanaseanu, Cristina Mihaela
    Molina, Joseph McDermott
    Antonovsky, Yuri
    Van Rensburg, Dirkie Johanna
    Rowe, Brian H.
    Flores-Figueroa, Jose
    Rewerska, Barbara
    Clark, Kay
    Keedy, Kara
    Sheets, Amanda
    Scott, Drusilla
    Horwith, Gary
    Das, Anita F.
    Jamieson, Brian
    Fernandes, Prabhavathi
    Oldach, David
    LANCET INFECTIOUS DISEASES, 2016, 16 (04): : 421 - 430
  • [33] Effect of addition of single dose of oral montelukast to standard treatment in acute moderate to severe asthma in children between 5 and 15 years of age: a randomised, double-blind, placebo controlled trial
    Todi, Vivek Kumar
    Lodha, Rakesh
    Kabra, S. K.
    ARCHIVES OF DISEASE IN CHILDHOOD, 2010, 95 (07) : 540 - 543
  • [34] Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial (vol 374, pg 1694, 2009)
    Sur, D.
    Lopez, A. L.
    Kanungo, S.
    LANCET, 2010, 376 (9750): : 1392 - 1392
  • [35] Efficacy and safety of the oral selective sphingosine-1-phosphate-1 receptor modulator VTX002 in moderately to severely active Ulcerative Colitis: results from a randomised, double-blind, placebo-controlled, phase 2 trial
    Sands, B. E.
    Panaccione, R.
    D'Haens, G.
    Schreiber, S.
    DuVall, A.
    Kierkus, J.
    Naik, S.
    Gilder, K.
    Yun, C.
    Sandborn, W. J.
    Walczak, M.
    Vermeire, S.
    Rubin, D. T.
    Peyrin-Biroulet, L.
    Danese, S.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I4 - I5
  • [36] Efficacy of oral amoxicillin-clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-controlled trial
    Goyal, Vikas
    Grimwood, Keith
    Ware, Robert S.
    Byrnes, Catherine A.
    Morris, Peter S.
    Masters, I. Brent
    McCallum, Gabrielle B.
    Binks, Michael J.
    Smith-Vaughan, Heidi
    O'Grady, Kerry-Ann F.
    Champion, Anita
    Buntain, Helen M.
    Schultz, Andre
    Chatfield, Mark
    Torzillo, Paul J.
    Chang, Anne B.
    LANCET RESPIRATORY MEDICINE, 2019, 7 (09): : 791 - 801
  • [38] Duvakitug (TEV-48574), an anti-TL1a monoclonal antibody, demonstrates efficacy and favourable safety as an induction treatment in adults with moderately to severely active Crohn's disease: results from a phase 2b, randomised, double-blind, placebo-controlled dose-ranging, basket trial (RELIEVE UCCD)
    Jairath, V
    Kierkus, J.
    Duvall, G. A.
    Danese, S.
    Sands, B. E.
    Ratiu-Duma, B.
    Singh, R.
    Barkay, H.
    Raphael, G.
    Reinisch, W.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i77 - i78
  • [39] Duvakitug (TEV-48574), an anti-TL1a monoclonal antibody, demonstrates efficacy and favourable safety as an induction treatment in adults with moderately to severely active ulcerative colitis: Results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging, basket trial (RELIEVE UCCD)
    Reinisch, W.
    Stepek, D.
    Kempinski, R.
    Danese, S.
    Sands, B. E.
    Ratiu-Duma, B.
    Singh, R.
    Barkay, H.
    Raphael, G.
    Jairath, V.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i79 - i80